2025-03-012026-02-282026-02-28false11815282CHIASONS MEDICAL LTD2026-06-04falseiso4217:GBPxbrli:pure118152822025-02-28118152822026-02-28118152822025-03-012026-02-28118152822024-02-29118152822025-02-28118152822024-03-012025-02-2811815282bus:SmallEntities2025-03-012026-02-2811815282bus:AuditExempt-NoAccountantsReport2025-03-012026-02-2811815282bus:FullAccounts2025-03-012026-02-2811815282bus:PrivateLimitedCompanyLtd2025-03-012026-02-2811815282core:WithinOneYear2026-02-2811815282core:AfterOneYear2026-02-2811815282core:WithinOneYear2025-02-2811815282core:AfterOneYear2025-02-2811815282core:ShareCapital2026-02-2811815282core:SharePremium2026-02-2811815282core:RevaluationReserve2026-02-2811815282core:OtherReservesSubtotal2026-02-2811815282core:RetainedEarningsAccumulatedLosses2026-02-2811815282core:ShareCapital2025-02-2811815282core:SharePremium2025-02-2811815282core:RevaluationReserve2025-02-2811815282core:OtherReservesSubtotal2025-02-2811815282core:RetainedEarningsAccumulatedLosses2025-02-2811815282core:LandBuildings2026-02-2811815282core:PlantMachinery2026-02-2811815282core:Vehicles2026-02-2811815282core:FurnitureFittings2026-02-2811815282core:OfficeEquipment2026-02-2811815282core:NetGoodwill2026-02-2811815282core:IntangibleAssetsOtherThanGoodwill2026-02-2811815282core:ListedExchangeTraded2026-02-2811815282core:UnlistedNon-exchangeTraded2026-02-2811815282core:LandBuildings2025-02-2811815282core:PlantMachinery2025-02-2811815282core:Vehicles2025-02-2811815282core:FurnitureFittings2025-02-2811815282core:OfficeEquipment2025-02-2811815282core:NetGoodwill2025-02-2811815282core:IntangibleAssetsOtherThanGoodwill2025-02-2811815282core:ListedExchangeTraded2025-02-2811815282core:UnlistedNon-exchangeTraded2025-02-2811815282core:LandBuildings2025-03-012026-02-2811815282core:PlantMachinery2025-03-012026-02-2811815282core:Vehicles2025-03-012026-02-2811815282core:FurnitureFittings2025-03-012026-02-2811815282core:OfficeEquipment2025-03-012026-02-2811815282core:NetGoodwill2025-03-012026-02-2811815282core:IntangibleAssetsOtherThanGoodwill2025-03-012026-02-2811815282core:ListedExchangeTraded2025-03-012026-02-2811815282core:UnlistedNon-exchangeTraded2025-03-012026-02-2811815282core:MoreThanFiveYears2025-03-012026-02-2811815282core:Non-currentFinancialInstruments2026-02-2811815282core:Non-currentFinancialInstruments2025-02-2811815282dpl:CostSales2025-03-012026-02-2811815282dpl:DistributionCosts2025-03-012026-02-2811815282core:LandBuildings2025-03-012026-02-2811815282core:PlantMachinery2025-03-012026-02-2811815282core:Vehicles2025-03-012026-02-2811815282core:FurnitureFittings2025-03-012026-02-2811815282core:OfficeEquipment2025-03-012026-02-2811815282dpl:AdministrativeExpenses2025-03-012026-02-2811815282core:NetGoodwill2025-03-012026-02-2811815282core:IntangibleAssetsOtherThanGoodwill2025-03-012026-02-2811815282dpl:GroupUndertakings2025-03-012026-02-2811815282dpl:ParticipatingInterests2025-03-012026-02-2811815282dpl:GroupUndertakingscore:ListedExchangeTraded2025-03-012026-02-2811815282core:ListedExchangeTraded2025-03-012026-02-2811815282dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-03-012026-02-2811815282core:UnlistedNon-exchangeTraded2025-03-012026-02-2811815282dpl:CostSales2024-03-012025-02-2811815282dpl:DistributionCosts2024-03-012025-02-2811815282core:LandBuildings2024-03-012025-02-2811815282core:PlantMachinery2024-03-012025-02-2811815282core:Vehicles2024-03-012025-02-2811815282core:FurnitureFittings2024-03-012025-02-2811815282core:OfficeEquipment2024-03-012025-02-2811815282dpl:AdministrativeExpenses2024-03-012025-02-2811815282core:NetGoodwill2024-03-012025-02-2811815282core:IntangibleAssetsOtherThanGoodwill2024-03-012025-02-2811815282dpl:GroupUndertakings2024-03-012025-02-2811815282dpl:ParticipatingInterests2024-03-012025-02-2811815282dpl:GroupUndertakingscore:ListedExchangeTraded2024-03-012025-02-2811815282core:ListedExchangeTraded2024-03-012025-02-2811815282dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-03-012025-02-2811815282core:UnlistedNon-exchangeTraded2024-03-012025-02-2811815282core:NetGoodwill2026-02-2811815282core:IntangibleAssetsOtherThanGoodwill2026-02-2811815282core:LandBuildings2026-02-2811815282core:PlantMachinery2026-02-2811815282core:Vehicles2026-02-2811815282core:FurnitureFittings2026-02-2811815282core:OfficeEquipment2026-02-2811815282core:AfterOneYear2026-02-2811815282core:WithinOneYear2026-02-2811815282core:ListedExchangeTraded2026-02-2811815282core:UnlistedNon-exchangeTraded2026-02-2811815282core:ShareCapital2026-02-2811815282core:SharePremium2026-02-2811815282core:RevaluationReserve2026-02-2811815282core:OtherReservesSubtotal2026-02-2811815282core:RetainedEarningsAccumulatedLosses2026-02-2811815282core:NetGoodwill2025-02-2811815282core:IntangibleAssetsOtherThanGoodwill2025-02-2811815282core:LandBuildings2025-02-2811815282core:PlantMachinery2025-02-2811815282core:Vehicles2025-02-2811815282core:FurnitureFittings2025-02-2811815282core:OfficeEquipment2025-02-2811815282core:AfterOneYear2025-02-2811815282core:WithinOneYear2025-02-2811815282core:ListedExchangeTraded2025-02-2811815282core:UnlistedNon-exchangeTraded2025-02-2811815282core:ShareCapital2025-02-2811815282core:SharePremium2025-02-2811815282core:RevaluationReserve2025-02-2811815282core:OtherReservesSubtotal2025-02-2811815282core:RetainedEarningsAccumulatedLosses2025-02-2811815282core:NetGoodwill2024-02-2911815282core:IntangibleAssetsOtherThanGoodwill2024-02-2911815282core:LandBuildings2024-02-2911815282core:PlantMachinery2024-02-2911815282core:Vehicles2024-02-2911815282core:FurnitureFittings2024-02-2911815282core:OfficeEquipment2024-02-2911815282core:AfterOneYear2024-02-2911815282core:WithinOneYear2024-02-2911815282core:ListedExchangeTraded2024-02-2911815282core:UnlistedNon-exchangeTraded2024-02-2911815282core:ShareCapital2024-02-2911815282core:SharePremium2024-02-2911815282core:RevaluationReserve2024-02-2911815282core:OtherReservesSubtotal2024-02-2911815282core:RetainedEarningsAccumulatedLosses2024-02-2911815282core:AfterOneYear2025-03-012026-02-2811815282core:WithinOneYear2025-03-012026-02-2811815282core:Non-currentFinancialInstrumentscore:CostValuation2025-03-012026-02-2811815282core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-03-012026-02-2811815282core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-03-012026-02-2811815282core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-03-012026-02-2811815282core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-03-012026-02-2811815282core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-03-012026-02-2811815282core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-03-012026-02-2811815282core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-03-012026-02-2811815282core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-03-012026-02-2811815282core:Non-currentFinancialInstrumentscore:CostValuation2026-02-2811815282core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-02-2811815282core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-02-2811815282core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-02-2811815282core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-02-2811815282core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-02-2811815282core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-02-2811815282core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-02-2811815282core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-02-2811815282core:Non-currentFinancialInstrumentscore:CostValuation2025-02-2811815282core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-02-2811815282core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-02-2811815282core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-02-2811815282core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-02-2811815282core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-02-2811815282core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-02-2811815282core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-02-2811815282core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-02-2811815282bus:Director12025-03-012026-02-2811815282bus:Director22025-03-012026-02-2811815282core:FurnitureFittingsToolsEquipment2025-02-2811815282core:FurnitureFittingsToolsEquipment2026-02-2811815282core:FurnitureFittingsToolsEquipment2025-03-012026-02-2811815282core:OtherMiscellaneousReserve2026-02-28

CHIASONS MEDICAL LTD

Registered Number
11815282
(England and Wales)

Unaudited Financial Statements for the Year ended
28 February 2026

CHIASONS MEDICAL LTD
Company Information
for the year from 1 March 2025 to 28 February 2026

Directors

CHIA, Janet
CHIA, Peng Sang, Dr

Registered Address

70 Wright Street
Hull
HU2 8JD

Registered Number

11815282 (England and Wales)
CHIASONS MEDICAL LTD
Balance Sheet as at
28 February 2026

Notes

2026

2025

£

£

£

£

Fixed assets
Tangible assets3253,828254,212
Investments416,110-
269,938254,212
Current assets
Debtors5228,719222,700
Cash at bank and on hand4,3059,368
233,024232,068
Creditors amounts falling due within one year6(32,288)(29,445)
Net current assets (liabilities)200,736202,623
Total assets less current liabilities470,674456,835
Net assets470,674456,835
Capital and reserves
Called up share capital2020
Other reserves(5,104)-
Profit and loss account475,758456,815
Shareholders' funds7470,674456,835
The financial statements were approved and authorised for issue by the Board of Directors on 4 June 2026, and are signed on its behalf by:
CHIA, Peng Sang, Dr
Director
Registered Company No. 11815282
CHIASONS MEDICAL LTD
Notes to the Financial Statements
for the year ended 28 February 2026

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)
Fixtures and fittings20
Office Equipment20
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
2.Average number of employees

20262025
Average number of employees during the year22
3.Tangible fixed assets

Land & buildings

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 March 25252,2941,5453,343257,182
At 28 February 26252,2941,5453,343257,182
Depreciation and impairment
At 01 March 25-7882,1822,970
Charge for year-151232383
On disposals--11
At 28 February 26-9392,4153,354
Net book value
At 28 February 26252,294606928253,828
At 28 February 25252,2947571,161254,212
4.Fixed asset investments

Other investments1

Total

££
Cost or valuation
Additions21,21421,214
Revaluations(5,104)(5,104)
At 28 February 2616,11016,110
Net book value
At 28 February 2616,11016,110
At 28 February 25--

Notes

1Other investments other than loans
5.Debtors: amounts due within one year

2026

2025

££
Other debtors228,599222,700
Prepayments and accrued income120-
Total228,719222,700
6.Creditors: amounts due within one year

2026

2025

££
Bank borrowings and overdrafts26,95829,445
Taxation and social security4,370-
Accrued liabilities and deferred income960-
Total32,28829,445
Included within bank borrowings and overdrafts is £26,958 (2025 - £29,445) which relates to amounts owed to the directors.
7.Fair value reserve

£
Transferred in period(5,104)
At 28 February 26(5,104)